{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:12:58Z","timestamp":1740136378403,"version":"3.37.3"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s10072-022-06239-w","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T02:02:43Z","timestamp":1656468163000},"page":"6593-6594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Teriflunomide-induced Raynaud\u2019s phenomenon: a serious adverse event, previously unreported"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7929-1055","authenticated-orcid":false,"given":"Javier","family":"Riancho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Delgado-Alvarado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyre","family":"Riancho-Zarrabeitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"issue":"14","key":"6239_CR1","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O\u2019Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP et al (2011) Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 365(14):1293\u20131303","journal-title":"N Engl J Med"},{"key":"6239_CR2","doi-asserted-by":"publisher","first-page":"727586","DOI":"10.3389\/fneur.2021.727586","volume":"12","author":"L Landete","year":"2021","unstructured":"Landete L, Perez-Miralles F, Garcia S, Belenguer A, Gascon F, Dominguez JA et al (2021) Treatment of multiple sclerosis with teriflunomide. Multicenter study of real clinical practice in the Valencian Community-Spain. Front Neurol 12:727586","journal-title":"Front Neurol"},{"issue":"6","key":"6239_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/BOR.0000000000000826","volume":"33","author":"AL Herrick","year":"2021","unstructured":"Herrick AL (2021) Raynaud\u2019s phenomenon and digital ulcers: advances in evaluation and management. Curr Opin Rheumatol 33(6):453\u2013462","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"6239_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.therap.2017.01.008","volume":"72","author":"E Bouquet","year":"2017","unstructured":"Bouquet E, Urbanski G, Lavigne C, Laine-Cessac P (2017) Unexpected drug-induced Raynaud phenomenon: analysis from the French national pharmacovigilance database. Therapie 72(5):547\u2013554","journal-title":"Therapie"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06239-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06239-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06239-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T04:05:26Z","timestamp":1666929926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06239-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":4,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["6239"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06239-w","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"17 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and informed\u00a0consent were obtained before publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}},{"value":"Patient\u2019s consent was obtained for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JR: JR has received travel grants or speaking fees from MERCK, SANOFI-GENZYME, ROCHE, BIOGEN and NOVARTIS.MDA: MDA has received travel grants or speaking fees from MERCK, NOVARTIS AND SANOFI-GENZYME.LRZ: no conflict of interest related to this issue.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}